
Opinion|Videos|July 22, 2024
Head-to-head Study of Upadacitnib and Dupilumab in Atopic Dermatitis (Level Up)
Author(s)Christopher G. Bunick, MD, PhD
An atopic dermatitis expert describes the results of the Level Up study, a phase 3b/4 trial comparing upadacitinib and dupilumab, which were recently presented at RAD 2024, focusing on the primary and secondary outcomes of the study.
Advertisement
Episodes in this series
- Head-to-head studies of systemic treatments and studies evaluating sequencing of systemic treatments are rare. Results of one such study, Level Up, were recently presented at RAD 2024. Can you describe the study briefly and discuss primary and secondary outcomes in phase 3b/4 study that compared upadacitnib and dupilumab (
Level Up , RAD 2024)? - What are implications of these results in everyday practice?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Olezarsen (Tryngolza) for Severe Hypertriglyceridemia
2
Delgocitinib Approval Fills a Long-Standing Gap in Chronic Hand Eczema Treatment
3
Q&A: CKM Care, IRA Policy, and Specialty Silos, With Rishi Wadhera, MD, MPP, MPhil
4
Q&A: Cardiometabolic Care Cascade Failure Points, with Rishi Wadhera, MD, MPP, MPhil
5
























































































